Bharat Biotech's covaxin faces another hurdle

• In a major development Brazil has suspended the clinical studies of Bharat Biotech's Covaxin.

• Bharat Biotech on Friday, July 23, 2021 announced cancellation of the MoU it had signed with Precisa Medicamentos and Envixia Pharamaceuticals, to launch the covaxin in the south=american country's market

• "In the Coordination of Clinical Research at Anvisa (Copec/GGMED) determined this Friday (23/7) the precautionary suspension of clinical studies of the Covaxin vaccine in Brazil The suspension was carried out as a result of a statement from the Indian company Bharat Biotech Limited International, sent to Anvisa on Friday (23/7), Anvisa, the Brazilian health regulator, said on Friday.

• Although the termination is only temporary it needs to be seen how the company displays its efficacy in front of the Brazillian officals.